ArteraAI and Movember Announce New Relationship
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, today anno [...]
ArteraAI Prostate Test Included in NCCN Guidelines
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Prostate Cancer have included the ArteraAI [...]
ArteraAI Included in the 2024 NCCN Guidelines® for Prostate Cancer
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced [...]
Here’s how AI will drive health care to meet consumer expectations
The rapid transformation of the health care landscape is undeniable. It is marked not only by groundbreaking technologies and [...]
Exclusive: ArteraAI nabs $20M to take personalized cancer care global
ArteraAI, a developer of AI tests to personalize therapy for cancer patients, raised $20 million in additional funding, CEO A [...]
ArteraAI Secures $20 Million in Funding to Further Personalize Cancer Therapy With Multimodal AI
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced [...]
Prostate cancer myths and common misconceptions from an oncologist amid high-profile cases
Amid a flurry of high-profile prostate cancer announcements, doctors are weighing in to debunk common myths about the disease [...]
ArteraAI Receives Medicare Payment Rate for the ArteraAI Prostate Cancer Test
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced [...]
CMS payment rate established for ArteraAI prostate cancer test
The Centers for Medicare & Medicaid Services (CMS) have established a payment rate for the ArteraAI prostate cancer test, [...]